Cardinal Health Stock Hits New 52-Week High (CAH)

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model.

NEW YORK ( TheStreet) -- Cardinal Health (NYSE: CAH) hit a new 52-week high Thursday as it is currently trading at $47.25, above its previous 52-week high of $47.23 with 3.5 million shares traded as of 1:50 p.m. ET. Average volume has been 3.6 million shares over the past 30 days.

Cardinal Health has a market cap of $15.81 billion and is part of the services sector and wholesale industry. Shares are up 13.6% year to date as of the close of trading on Wednesday.

Cardinal Health, Inc., a healthcare services company, provides pharmaceutical and medical products and services in the United States and internationally. The company operates in two segments, Pharmaceutical and Medical. The company has a P/E ratio of 13.8, below the S&P 500 P/E ratio of 17.7.

  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass.

TheStreet Ratings rates Cardinal Health as a buy. The company's strengths can be seen in multiple areas, such as its growth in earnings per share, increase in net income, notable return on equity, good cash flow from operations and increase in stock price during the past year. We feel these strengths outweigh the fact that the company shows low profit margins. You can view the full Cardinal Health Ratings Report.

See all 52-week high stocks or get investment ideas from our investment research center.

Exclusive Offer: Jim Cramer's 'go-to' small/mid-cap guru Bryan Ashenberg only buys stocks he thinks could return 50-100% See his top picks for 14-days FREE.
null

If you liked this article you might like

FDA Official Calls for Ending Codeine Use in Kids Cough Products

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids

Cramer: Finding the Flaws in Amazon

Cardinal Health: Cramer's Top Takeaways

Measure the Meaning of This Rally: Cramer's 'Mad Money' Recap (Tues 8/22/17)